Table 2.

Comparing the clinical outcomes at 15 months of relative risk estimates for death, myocardial infarction, and stent thrombosis in diabetic and non-diabetic patients treated with ZES (n = 333) or EES (n = 333)

	Diabetic patients				Non-diabetic patients
Outcome	ZES	EES	Relative risk (95% CI)	P Value	ZES	EES	Relative risk (95% CI)	P Value
Adverse cardiac events	16 (18.8%)	4 (4.8%)	4.95 (1.86-8.82)	0.0003	21 (8.5%)	8 (3.2%)	1.96 (1.37-2.69)	0.008
All-cause death	7 (8.2%)	4 (4.7%)	1.57 (0.47-3.28)	0.32	9 (3.6%)	6 (2.4%)	1.61 (0.87-2.37)	0.069
Cardiac death	3 (3.5%)	1 (1.2%)	3.12 (0.28-14.9)	0.21	3 (1.2%)	2 (0.8%)	1.32 (0.51-2.96)	0.71
Myocardial infarction	4 (4.7%)	1 (1.2%)	8.09 (1.32-64.7)	0.03	4 (1.6%)	2 (0.8%)	1.73 (0.39-3.95)	0.31
Stent thrombosis	1 (1.2%)	0 (0%)	-	-	2 (0.8%)	1 (0.4%)	1.79 (0.69-5.65)	0.39
Target lesion revascularization	12 (14.1%)	1 (1.2%)	11.7 (2.59-47.1)	0.002	13 (5.2%)	4 (1.6%)	2.85 (1.67-4.89)	0.001